Pancreatic Cancer Survivor Champions Fight for Better Treatments
A mother’s battle with pancreatic cancer inspires a new fight for improved treatment options and hope for patients.
2 min read
Resa Reddick Cancro, a mother and a fighter, battled pancreatic cancer with unwavering strength. Her battle ended in March 2026, after 19 months of fighting. Her daughter, who was in the final stages of high school, remembers the milestones she was determined to witness — her senior prom, college move-in day, and more. These moments, she says, were not just personal but deeply meaningful for her family.
A Personal Battle Against a Devastating Disease
Diagnosed in early August 2024, Resa’s journey with pancreatic cancer was both brave and tragic. Despite receiving two types of chemotherapy and two types of radiation, the disease proved too aggressive. Her daughter recalls how, even in the face of a terminal diagnosis, her mother never lost her determination to fight. The emotional toll on the family was immense, as they tried to live their lives while preparing for the inevitable.
Hope in Emerging Therapies
Pancreatic cancer remains one of the deadliest cancers, with most patients dying within a year of diagnosis. Only about 13% survive five years. In 2026, an estimated 67,530 Americans will be diagnosed, and 52,740 will die from the disease. The rising incidence of the disease has made it a growing public health concern, with cases climbing rapidly.
The Future of Treatment: Combination Therapies
Recent developments in treatment offer a glimmer of hope. A promising combination of two investigational drugs — daraxonrasib and vopimetostat — has shown early success. In a recent study, 82% of previously treated patients experienced tumor shrinkage, with an 88% progression-free survival rate. These preliminary results suggest that such combination therapies could significantly improve outcomes for pancreatic cancer patients.
Collaboration for Patient Survival
Developing these therapies requires collaboration between companies, despite differing business interests. While scientific rigor is essential, the urgency of patients facing imminent death cannot be ignored. Companies like Revolution Medicines and Tango Therapeutics must work together to accelerate research and bring effective treatments to patients as quickly as possible.
A Call for Urgency and Compassion
Resa’s daughter now advocates for the next families facing pancreatic cancer. She believes that biotechnology companies have a responsibility to prioritize patient needs over market competition. The urgency of developing new treatments must match the urgency of patients’ lives. Her mother’s fight for every extra day is a reminder that for many families, pancreatic cancer steals milestones and moments that can never be reclaimed.
Source: PJ Media
